Tagworks Pharmaceuticals

Executive Summary

Tagworks Pharmaceuticals is a Netherlands-based biotechnology company pioneering its proprietary Click-to-Release technology, which leverages in vivo click chemistry to enable controlled drug activation specifically at tumor sites and deactivation off-target. Founded in 2017, the company aims to improve the therapeutic window of potent cancer treatments, particularly antibody-drug conjugates (ADCs) and radiopharmaceuticals. By allowing precise control over drug release, Tagworks' platform seeks to enhance efficacy while reducing systemic toxicity, a critical challenge in oncology. The company is currently in Phase 1 development, with no disclosed financials or partnerships, but its novel approach has the potential to differentiate it in the competitive ADC and radiopharmaceutical landscape. Tagworks' technology has broad applicability, and early clinical data will be key to validating its platform and attracting strategic collaborations.

Upcoming Catalysts (preview)

• H2 2026Phase 1 data readout for lead ADC candidate30% success
• 2027Partnership or licensing deal for Click-to-Release platform40% success
• Q1 2027Preclinical proof-of-concept data for radiopharmaceutical program50% success